FDA Approves Benicar for the Hypertension Treatment in Children and Adolescents 6-16 old

FDA Approves Benicar for the Hypertension Treatment in Children and Adolescents 6-16 old.


US Food and Drug Administration (FDA) has approved the curing of euphoric blood influence Benicar (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age liprocil and cialis side affects. Benicar was from the outset approved in 2002 for the therapy of hypertension in adults.



Approximately 5 percent, or 3,6 million, American children be reduced from maximum blood pressure, with the preponderance inobservant they have the condition. Studies have also found that the commonplace blood insistence of American children is on the rise, in equivalent with the increase of children's weight Duphaston efectos. In fact, an inquiry of nearly 40 years of civil surveys of high blood compel trends in children and adolescents showed that the prevalence of glad blood pressure among this group has been growing since the departed 1980's.



A "As hypertension is on the take off also in a younger population, Daiichi Sankyo believes it is worthy to help doctors meet the dare of treating these pediatric patients by providing a remedying option to help people effectively preside over their hypertension," said Reinilde Heyrman, MD, Vice President Clinical Development - Operations, Daiichi Sankyo Pharma Development.



Pediatric hypertension is closely linked to boyhood obesity, as pot-bellied children are at approximately a three-fold higher endanger for hypertension than non-obese children. Additionally hypertension during teens has been shown to be an confident hazard factor for hypertension in adulthood, and to be associated with antique markers of cardiovascular disease, making it consequential to treat this working order in children and adolescents.